Last reviewed · How we verify
Heliox21
Heliox21 is a mixture of helium and oxygen used to reduce the work of breathing in patients with respiratory distress.
Heliox21 is a mixture of helium and oxygen used to reduce the work of breathing in patients with respiratory distress. Used for Treatment of respiratory distress in patients with status asthmaticus or severe COPD.
At a glance
| Generic name | Heliox21 |
|---|---|
| Sponsor | University College, London |
| Drug class | Respiratory gas mixture |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Heliox21 works by decreasing the density of the airway gas, making it easier for patients to breathe. This can be particularly beneficial for patients with conditions such as status asthmaticus or severe chronic obstructive pulmonary disease (COPD).
Approved indications
- Treatment of respiratory distress in patients with status asthmaticus or severe COPD
Common side effects
- Respiratory acidosis
Key clinical trials
- Effect of Heliox on RSV Bronchiolitis (PHASE3)
- Physiological Response to Heliox21 and Air O2 (PHASE4)
- NCPAP + Heliox as a Treatment for Infant Respiratory Distress Syndrome (RDS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heliox21 CI brief — competitive landscape report
- Heliox21 updates RSS · CI watch RSS
- University College, London portfolio CI